Home > Haematology > ASH 2021 Focus on CAR T-Cell Therapy > Welcome to our Focus Edition on CAR T-cell therapy news

Welcome to our Focus Edition on CAR T-cell therapy news


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ASH 2021
orig text:

Welcome to our Focus Edition on CAR T cell therapy news, which was presented at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, USA, from 11-14  December 2021. It was truly energising to be back at a medical conference, and ASH21 did not disappoint! The 3 phase 3 clinical trials reporting there about second-line use of CAR-T therapies for Diffuse Large B-Cell Lymphoma (DLBCL) were certainly one of the biggest stories to role out during the meeting. Two of the trials reported clear clinical benefit, but -surprisingly- the third one did not, which made for some extraordinary discussions. Medicom’s Medical Science Officer, Dr Rachel Giles, went to ASH21 and interviewed a series of 7 experts presenting there about this topic, moderated a panel discussion of thought leaders in this field, was the editor for 10 accompanying articles you will find in this Focus, and generated a podcast on the topic as well. Read, watch, and/or listen to catch up on the latest news in CAR T-cell therapy in DLBCL! Stay safe and stay healthy!


parsed elements:




Source with stripped tags:

Welcome to our Focus Edition on CAR T cell therapy news, which was presented at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, USA, from 11-14  December 2021. It was truly energising to be back at a medical conference, and ASH21 did not disappoint! The 3 phase 3 clinical trials reporting there about second-line use of CAR-T therapies for Diffuse Large B-Cell Lymphoma (DLBCL) were certainly one of the biggest stories to role out during the meeting. Two of the trials reported clear clinical benefit, but -surprisingly- the third one did not, which made for some extraordinary discussions. Medicom’s Medical Science Officer, Dr Rachel Giles, went to ASH21 and interviewed a series of 7 experts presenting there about this topic, moderated a panel discussion of thought leaders in this field, was the editor for 10 accompanying articles you will find in this Focus, and generated a podcast on the topic as well. Read, watch, and/or listen to catch up on the latest news in CAR T-cell therapy in DLBCL! Stay safe and stay healthy!


Posted on